Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 218,276,313 papers from all fields of science
Search
Sign In
Create Free Account
milameline
Known as:
1,2,5,6-tetrahydro-1-methyl-3-pyridinecarboxaldehyde O-methyloxime monohydrochloride
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
Narrower (1)
CI 979
Broader (2)
Dihydropyridines
Oximes
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
Milameline: Nonselective, Partial Muscarinic Receptor Agonist for the Treatment of Alzheimer's Disease?
A. Heidrich
,
M. Rösler
2006
Corpus ID: 496433
Alzheimer’s disease (AD) is a neurodegenerative disorder clinically characterized by a progressive loss of cognitive functions…
Expand
2006
2006
Combined cerebral blood flow effects of a cholinergic agonist (milameline) and a verbal recognition task in early Alzheimer’s disease
J. Trollor
,
P. Sachdev
,
W. Haindl
,
H. Brodaty
,
W. Wen
,
Brenda M. Walker
Psychiatry and Clinical Neurosciences
2006
Corpus ID: 39650765
Abstract RU 35926/CI‐979 (milameline) is a partial muscarinic agonist with promnestic effects in animal models. Preliminary…
Expand
2002
2002
Detecting regional cerebral blood flow changes in Alzheimer's patients after milameline treatment: activation or baseline SPECT?
X. Zheng
Journal of Nuclear Medicine Technology
2002
Corpus ID: 15973729
UNLABELLED The purpose of this study was to evaluate the effectiveness of activation versus baseline SPECT in detecting the…
Expand
Highly Cited
2000
Highly Cited
2000
Interrater Reliability of the Clinical Dementia Rating in a Multicenter Trial
K. Rockwood
,
D. Strang
,
C. MacKnight
,
R. Downer
,
J. Morris
Journal of The American Geriatrics Society
2000
Corpus ID: 31522657
OBJECTIVE: To test the interrater reliability of the Clinical Dementia Rating (CDR) in a multicenter clinical trial.
Highly Cited
1999
Highly Cited
1999
Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats.
H. Shannon
,
J. Hart
,
+9 authors
Michael D B Swedberg
Journal of Pharmacology and Experimental…
1999
Corpus ID: 5174976
The purpose of our studies was to determine the effects of muscarinic receptor agonists on conditioned avoidance responding in…
Expand
1999
1999
In vitro characterisation of the muscarinic receptor partial agonist, sabcomeline, in rat cortical and heart membranes.
J. Watson
,
A. Hunter
,
A. Brown
,
D. Middlemiss
European Journal of Pharmacology
1999
Corpus ID: 44804543
1999
1999
Combining tacrine with milameline reverses a scopolamine-induced impairment of continuous performance in rhesus monkeys
M. Callahan
Psychopharmacology
1999
Corpus ID: 25387701
Abstract Rationale: Cholinomimetic therapy in Alzheimer’s disease (AD) has been hampered by narrow efficacious dose ranges and…
Expand
1999
1999
Muscarinic Receptor Agonists in Alzheimer’s Disease
A. Fisher
1999
Corpus ID: 68661103
Research into and development of selective muscarinic receptor agonists for the treatment of Alzheimer’s disease is based on the…
Expand
Highly Cited
1999
Highly Cited
1999
Functional comparison of muscarinic partial agonists at muscarinic receptor subtypes hM1, hM2, hM3, hM4 and hM5 using microphysiometry
M. Wood
,
K. L. Murkitt
,
+4 authors
D. Middlemiss
British Journal of Pharmacology
1999
Corpus ID: 24732315
This study describes the pharmacological comparison of the muscarinic partial agonists sabcomeline, xanomeline and milameline at…
Expand
Highly Cited
1998
Highly Cited
1998
Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effects
F. Bymaster
,
Petra A. Carter
,
+12 authors
P. Sauerberg
Brain Research
1998
Corpus ID: 27857418
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE